GlassScriptPhysician profile
John Ireland
NPI 1881166312
$2,442.14
in general payments reported to CMS, 2019-2025
23 companies · $538 in 2025
The $538 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $477 · 2023: $454 · 2024: $635 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $539.96 | 2021-2025 | Omnipod |
| Lilly USA, LLC | $350.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $264.31 | 2021-2025 | Tymlos |
| Abbvie INC. | $240.77 | 2021-2025 | |
| Dexcom, INC. | $150.95 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.01 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $126.64 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $119.37 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Amneal Pharmaceuticals LLC | $115.04 | 2021-2025 | Unithroid |
| Mannkind Corporation | $74.61 | 2024-2025 | |
| Sequel Med Tech, LLC | $47.46 | 2025 | Twiist |
| Beta Bionics, INC. | $46.49 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $29.55 | 2023-2025 | Minimed 780g |
| Kyowa Kirin, INC. | $26.58 | 2024 | Crysvita |
| Pfizer INC. | $25.23 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.21 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.55 | 2025 | Gvoke Hypopen |
| Amgen INC. | $21.52 | 2023 | Evenity, Prolia |
| Cequr Corporation | $20.58 | 2023 | Cequr Simplicity |
| Horizon Therapeutics Plc | $20.48 | 2023 | Tepezza |
| Ibsa Pharma INC. | $19.66 | 2023 | Tirosint, Licart |
| Tandem Diabetes Care, INC. | $16.32 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ireland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.